Protocol Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications

Sponsor: Dragonfly

Protocol Number: DF9001-001

Key Criteria

EGFR + Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in selected indications
– NSCLC
– HNSCC
– CRC
– Esophageal adenocarcinoma
– Gastric cancer
– Renal cell carcinoma
– Pancreatic Cancer

Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.

Able and willing to have a fresh tumor biopsy obtained during the screening window and an on-treatment biopsy for pharmacodynamic analysis.

Talking Points

Scroll to Top